Application Area: Drug Development
202 Results for 'Drug Development'
- Technologies (20)
- Collaborations (6)
- Team (0)
- News (133)
- Pages (0)
- Multimedia (43)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 20
-
DNA Nanoswitch Calipers for Single-Molecule Proteomics
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Lactation Biologics: Increasing Milk Production for Healthier Babies
Lactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. -
eRNA: Enzymatic RNA synthesis for better drugs
EnPlusOne Biosciences is enabling RNA oligonucleotide manufacturing at scale, meeting the increasing demand for RNA drugs with an enzymatic process that is more efficient and creates a smaller environmental footprint.
Collaborations 6
-
Brain Targeted Therapeutic Collaboration
Combine our shuttles with your drugs to create new brain targeted therapeutics for patients. -
Brain Shuttle Research Sponsorship & Licensing
Enabling brain-targeted drug development through non-exclusive licensing and pre-competitive research sponsorship. -
Bridging the Funding Gap for Brain Therapeutics
A unique opportunity to help develop a new generation of brain targeted drugs -
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics.
News 133
Multimedia 43
-
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University -
Video/AnimationMice Don’t Menstruate: Reimagining Women’s Health Using Organ Chips with Dr. Donald IngberIn this episode, host Sharon Kedar, Co-Founder of Northpond Ventures, is joined by Dr. Donald Ingber, Founding Director at Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Ingber’s commitment to following his passion has led him to countless medical and technological breakthroughs, including Organ Chip technology. These incredible chips recreate the structure and... -
Video/AnimationAtlantic Health Research Spotlight: Finding Balance in Bipolar Disorder Through Drug Prediction and Organoid-Based Drug ScreeningInnovation has disrupted care as we know it. Challenges with access, complex diseases, and care delivery persist, but so do areas of opportunity for emerging tech and discoveries. The Atlantic explored gene editing, artificial intelligence, climate change, weight-loss and diabetes treatments, and more at their Annual Health Summit. The Wyss’ Director of Synthetic Biology, Jenny... -
Video/AnimationReimagine the World – Volume 3 – Northpond EditionThe Wyss Institute’s alliance with Northpond Labs supports early-stage, transformative research with strong translation potential. Hear Northpond Ventures co-founders Michael Rubin and Sharon Kedar explain why they decided to partner with the Wyss, as well as the leaders of various Wyss projects and startups about how support from Northpond has helped accelerate their technologies to... -
Video/AnimationEnhancing Lactation to Improve Infant and Maternal HealthLactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. Credit: Wyss Institute at Harvard University -
Video/AnimationBridging science, engineering, and art: from mechanobiology to Human Organs-on-ChipsIn this Marsilius Lecture, Wyss Founding Director Don Ingber shares his personal path from a serendipitous experience in an undergraduate art class that led to his discovery of how living cells are constructed using “tensegrity” architecture and how this contributed to the birth of the field of Mechanobiology to his more recent work on human...